What the research reports
View evidenceA 48-week Phase 2 trial reported a mean body-weight reduction of 24.2% in one study arm.
Image 01 / 01Research compound
Retatrutide
Triple agonist — GIP, GLP-1, glucagon · Phase 3
Metabolic research / compoundCA$115.00
Select variant
Retatrutide/
CA$115.00
Key findings
A Phase 2 MRI-PDFF substudy reported least-squares mean relative liver-fat reductions from 42.9% to 82.4% at week 24 across study arms.
How it works
Preclinical work characterised retatrutide as a triple-receptor agonist.
Where the evidence comes from
View evidenceRetatrutide findings shown here come from Phase 2 clinical trials and preclinical receptor, cell, and mouse studies.
Jastreboff et al., NEJM, 2023 · PubMed · Sanyal et al., Nature Medicine, 2024 · DOI · Coskun et al., Cell Metabolism, 2022 · PubMed
What's still open
Retatrutide liver-fat findings shown here concern the cited 98-person MRI-PDFF substudy.
Identity & specifications
Retatrutide
- Form
- Lyophilized peptide
- CAS
- 2381089-83-2
- Formula
- C221H342N46O68
- Molecular weight
- 4731.3 g/mol
Documentation
Published analytical record
Open certificate PDFRET-317
- Record type
- External analytical record
- Report
- COA-2026-SC-01250
- Laboratory
- SideChain Analytics
- Reported
- August 23, 2026
- Method
- LC-MS/MS
- Chromatographic purity
- 99.3%
- Verification code
- PTC-2PGJMS4N
